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ABSTRACT 
 
Macrophages are key orchestrators of the innate immune response with a 
dynamic role in the promotion and resolution of inflammation. Macrophage polarization 
to a pro-inflammatory or ant-inflammatory phenotype must be tightly controlled to 
maintain appropriate responses to stimuli as well as to maintain tissue homeostasis. The 
nutrient and energy sensor Mammalian Target of Rapamycin (mTOR) integrates 
upstream signals from the PI3K/Akt pathway to orchestrate cellular protein, lipid, and 
glucose metabolism. This key metabolic pathway has been implicated in T-helper cell 
skewing and in the innate immune regulation. The mechanisms of innate immune 
regulation by mTOR are currently unclear as most studies use pharmacological 
inhibitors with potential off target effects. In this study, we use a novel model of TSC1 
deficiency in myeloid lineage cells to elucidate a role for mTOR in macrophage 
polarization. We show, for the first time, that Tsc1-deficiency and constitutive mTORC1 
activity in macrophages leads to a marked defect in M2 polarization when stimulated 
with the Th2 cytokine IL-4. Tsc1-deficient macrophages display attenuated Akt signaling 
in response to IL-4 consistent with negative feedback of mTORC1 on upstream 
IRS2/PI3K signaling, and we demonstrate that this parallel signaling pathway is critical 
for induction of a subset of M2 markers. Tsc1-deficient macrophages fail to upregulate 
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the M2 genes Pgc-1!, Arg-1, Fizz-1, and Mgl1 in addition to other M2 markers despite 
normal STAT6 signaling in response to IL-4. Consistent with downregulation of Pgc-1!, 
Tsc1-deficient macrophages also display defects in fatty acid metabolism and 
mitchochondrial biogenesis. Furthermore, LPS stimulation in Tsc-1 deficient 
macrophages leads to an enhanced inflammatory response with increased production of 
pro-inflammatory cytokines. We believe that Tsc1-deficient macrophages are a model of 
constitutive mTORC1 activity akin to obesity, where chronic nutrient excess leads to 
increases in mTORC1 activity, attenuation of IRS/PI3K/Akt signaling, and defective M2 
polarization of macrophages in metabolic tissues. 
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Introduction 
Mammalian target of rapamycin (mTOR) is a key nutrient and energy sensor that 
integrates cell surface receptor signals and amino acid availability to regulate cell 
growth, proliferation and survival1. mTOR, a serine/threonine kinase, exists in two 
complexes in the cell; mTORC1 containing rapamycin-senstive Raptor and mTORC2 
containing rapamycin-insensitive Rictor, both of which are positively by insulin, cytokines 
and growth factors  mTOR Complex 1 regulates protein synthesis and ribosomal 
biogenesis through phosphorylation of downstream targets S6K1/2 and the translational 
repressor 4E-BP1 A recent study also demonstrates that mTORC1 promotes glycolytic 
metabolism as well as lipid and cholesterol biosynthesis through regulation of HIF-1$ 
and SREBP1/2, respectively2. mTORC2 function, on the other hand is not well 
understood. The tuberous sclerosis repressor complex containing TSC1 and TSC2, 
integrates upstream signals of nutrient and energy availability to regulate mTORC1 and 
mTORC2 activity3. The TSC complex possesses GTPase Activating Protein activity, 
which exerts effects on the small GTPase protein Rheb3. In the absence of nutrient and 
growth factor signaling, the TSC complex negatively regulates mTORC1 activity by 
maintaining Rheb in the GDP-bound, inactive state3. Conversely, in the presence of 
nutrients and growth factors, PI3K-mediated Akt activation leads to phosphorylation and 
inactivation of TSC2 GAP activity allowing Rheb to become GTP-bound and activate 
mTORC13. Mutations in the TSC complex thus lead to aberrant mTORC1 activity, which 
is notably linked to the tuberous sclerosis genetic disorder, increased cancer cell 
proliferation, and insulin resistance1,4,5. Mouse models of Tsc1 or Tsc2 genetic ablation 
are increasingly utilized to elucidate the function of mTORC1 in several cell types and 
tissues both in vitro and in vivo. 
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A key event that occurs upstream of mTORC1 activation is phosphorylation of 
the serine/threonine kinase Akt3. PI3K-mediated PIP2 to PIP3 conversion downstream of 
the insulin receptor and other cytokine and growth factor receptors activates PDK1, 
which phosphorylates Akt at threonine 308, whereas PI3K activation mTORC2 leads to 
Akt phosphorylation at serine 4733. Downstream, Akt inactivates the TSC repressor 
complex in addition to phosphorylating the transcription factor, FOXO1, leading to 
nuclear exclusion3.  Constitutive mTORC1 in Tsc1 or Tsc2-null cells results in negative 
feedback inhibition of upstream Akt signaling3. This negative feedback inhibition, likely a 
mechanism to maintain inducbility of these signaling pathways, occurs by two defined 
mechanisms; first, an increase in S6K1 activity downstream of mTORC1 in Tsc-null cells 
leads to serine phosphorylation of insulin receptor substrates (IRS1/2), which 
destabilizes these proteins and attenuates downstream insulin-stimulated Akt 
phosphorylation3,5. Second, loss of the TSC complex in addition to direct inhibition of 
S6K1 leads to reduced mTORC2-mediated Akt phosphorylation at serine 473, in 
addition to decreased activity of other mTORC2 targets3. Thus, loss of either Tsc1 or 
Tsc2 leads to a decrease in inducible Akt phosphorylation and activity due to constitutive 
mTORC1 resulting in insulin resistance, and this is partially reversed by the mTORC1 
inhibitor rapamycin in hepatocytes, MEFs, and adipocytes2,6,7.  
Several studies now demonstrate that mTOR is a central regulator of key 
metabolic processes in a number of cells types, but the role of mTOR in regulating 
immune cell function is just beginning to emerge. A recent study, for example, elucidated 
a role for mTOR kinase in the regulation of T-helper cell function. The study identified 
that mTORC1 was essential for differentiation of naive T-cells into pro-inflammatory Th1 
cells, while mTORC2 was essential for differentiation into anti-inflammatory Th2 cells8. 
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Another study in dendritic cells, a component of the innate immune system, reported that 
knockdowns of Tsc2 leads to decreased pro-inflammatory cytokine secretion with 
bacterial stimulation, while mTORC1 inhibition with rapamycin leads to enhanced pro-
inflammatory responses9. While there is evidence of mTOR regulating both the innate 
and adaptive immune system in T-helper cells and dendritic cells, the role of mTOR in 
regulating macrophage cell function and metabolism remains poorly understood. 
Macrophages represent a key component of the innate immune system responsible for 
orchestrating the inflammatory response and host defense10. Circulating monocytes 
derived from the bone marrow are differentiated into macrophages in tissues by 
cytokines or growth factors that polarize macrophages into pro-inflammatory or anti-
inflammatory phenotypes10. Macrophages activated by lipopolysaccharide, a component 
of bacteria, and Interferon-! are pro-inflammatory and are referred to as “classically 
activated,” or M110. M1 macrophages promote tissue damage and inflammation by 
producing cytokines, such as TNF-", IL-6 and IL-1#, chemokines, such as MCP-1, and 
lipid mediators, such as prostaglandins and leukotrienes10. Additionally, M1 
macrophages dramatically increase iNOS mRNA expression and activity, which 
generates nitric oxide from L-arginine substrate to promote bacterial killing10,11. 
Conversely, macrophages activated by Interleukin-4 are anti-inflammatory and are 
referred to as “alternatively activated,” or M212. M2 macrophages promote the resolution 
of inflammation and tissue repair by producing factors such as Interleukin-10, a potent 
anti-inflammatory cytokine, in addition to other M2 markers, such as Fizz1, C-type lectins 
Mgl1/2, Mrc1, and Ym113. A hallmark of M2 macrophages is an increase in Arginase-1 
expression and activity, which utilizes L-Arginine as a substrate to generate L-ornithine, 
an amino acid used for polyamine synthesis, and the byproduct urea12,14,15. In addition to 
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orchestrating the immune response, circulating monocytes and resident macrophages 
are critical for maintaining tissue homeostasis16,17. The pivotal role of these immune cells 
thus necessitates a careful balance between pro-inflammatory M1 and anti-inflammatory 
M2 function16,17. If the balance of M1 and M2 macrophages is disrupted, this could lead 
to inappropriate responses to environmental stimuli and exacerbated pathology in 
certain settings16. In the pathological context of obesity, for example, adipose tissue 
macrophages undergo a phenotypic switch from M2 to M1, which potentiates 
inflammation and associated insulin resistance18. 
Not only do M1 and M2 macrophages have divergent and opposing functions, 
they also have distinct metabolic programs to meet cellular energy demands during 
activation. Alternatively activated M2 macrophages utilize fatty acid oxidation mediated 
by the nuclear receptors PPAR$ and PPAR!, while classically activated M1 
macrophages primarily rely on glycolytic metabolism, mediated by HIF-1"14,19.  
Particularly in M2 macrophages, regulation of the metabolic program and expression of 
M2 markers necessary for alternative activation are intricately linked. For instance, the 
fatty acid sensors peroxisome proliferator activated receptors ! and " (PPAR! and ") 
promote fatty acid oxidation and M2 gene marker expression in conjunction with the 
coactivator PGC-1#14. Two notable studies demonstrate that loss of either PPAR! or 
PPAR" in myeloid lineage cells leads to a defect in M2 polarization20,21. Specifically, 
PPAR"-KO macrophages have reduced expression of a subset of M2 genes, such as 
the C-type lectin family members Mgl1 and Mgl2, as well as Arginase-1 upon IL-13 
stimulation21. PPAR#-KO macrophages have defective Arginase-1 expression and 
activity in addition to marked defects in fatty oxidation upon IL-4 stimulation20. The PPAR 
coactivator, PGC-1#, is also critical for M2 differentiation, with PGC-1# knockdown in 
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macrophages leading to decreased Arginase-1 activity and expression concomitant with 
defects in fatty acid oxidation22. In addition to PPARs, the transcription factor STAT6 is 
indispensible for M2 polarization14,23. STAT6 is phosphorylated by Janus Kinase-1 
downstream of IL-4 receptor signaling, which leads to dimerization and nuclear 
translocation12. STAT6 then increases expression of several M2 genes and Pgc-1!, as 
well as genes involved in oxidative metabolism22. PGC-1# serves as a transcriptional 
coactivator for STAT6 as well as PPAR", and PPAR!, which promotes the metabolic 
shift to oxidative metabolism and the full expression of M2 markers14,16. In addition to 
STAT6 and PPAR activation, IL-4 Receptor signaling in macrophages leads to activation 
of IRS2 and downstream PI3K/Akt signaling12,24. The IL-4R$ chain specifically engages 
IRS2 in response to IL-4 leading to downstream Akt activation, an event shown to be 
critical for induction of the M2 gene IL-1R antagonist24,25. Proper Akt signaling 
downstream of the IL-4 Receptor in parallel with JAK/STAT6 signaling and PPAR 
activation may be important for maximal expression of M2 markers and implementation 
of metabolic programs in M2 polarization.  
In this study, we use Tsc1-deficient macrophages to investigate the role of 
mTOR in macrophage polarization. We show, for the first time, that Tsc1-deficiency and 
constitutive mTORC1 activity in macrophages leads to a marked defect in M2 
polarization when stimulated with the Th2 cytokine IL-4. Tsc1-deficient macrophages 
display attenuated Akt signaling in response to IL-4 consistent with negative feedback of 
mTORC1 on upstream IRS2/PI3K signaling, and we demonstrate that this parallel 
signaling pathway is critical for induction of a subset of M2 markers. Tsc1-deficient 
macrophages fail to upregulate the M2 genes Pgc-1!, Arg-1, Fizz-1, and Mgl1 in 
addition to other M2 markers despite normal STAT6 signaling in response to IL-4. 
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Consistent with downregulation of Pgc-1!, Tsc1-deficient macrophages also display 
defects in fatty acid metabolism and mitchochondrial biogenesis. Furthermore, LPS 
stimulation in Tsc-1 deficient macrophages leads to an enhanced inflammatory response 
with increased production of pro-inflammatory cytokines. We believe that Tsc1-deficient 
macrophages are a model of constitutive mTORC1 activity akin to obesity, where 
chronic nutrient excess leads to increases in mTORC1 activity, attenuation of 
IRS/PI3K/Akt signaling, and defective M2 polarization of macrophages in metabolic 
tissues.  
Materials and Methods 
Mice 
Mice with floxed Tsc1 alleles (Tsc1fl/fl) were kindly provided by Brendan Manning 
(Harvard School of Public Health) and LysozymeM-Cre transgenic mice were kindly 
provided by Chihao Lee (Harvard School of Public Health). Rictorfl/fl and Rictorfl/fl 
ubiquitinC-Cre ERT2 mice injected with tamoxifen were kindly provided by David 
Sabatini. All mice were on a B6 background and were described previously26,27,39. For 
targeted deletion of Tsc1 in myeloid lineage cells, Tsc1fl/fl mice were crossed to LysMCre 
transgenic mice. Genotype of the mice was confirmed by PCR of tail DNA with primers 
to detect the Tsc1 loxP alleles and the LysMCre transgene. All mice were maintained at 
Harvard Medical School, and procedures were performed in accordance with the 
guidelines set forth by the Institutional Animal Care and Use Committee.  
Bone Marrow Derived Macrophages 
Bone marrow derived macrophages were prepared as previously described40. 
Briefly, femurs were removed from mice after euthanasia with CO2, and cells were 
subsequently liberated from the femur bones using a mortar and pestle. For macrophage 
 7 
differentiation, bone marrow derived cells were plated in petri dishes with complete 1640 
RPMI media (10% FCS, Penicilin/Streptomycin, 2mM L-Glutamine) supplemented with 
MCSF-containing L929 cell supernatant for seven days. After seven days, MCSF 
differentiated macrophages were harvested with PBS + 2mM EDTA and plated in tissue 
culture dishes for subsequent experiments. For M1 polarization, 0.5x106 were plated in 
12-well tissue culture dishes and treated with 10ng/ml LPS (Inivivogen). For M2 
polarization, cells were treated with 10ng/ml IL-4 (Peprotech).  
Reagents and Antibodies 
To examine mTORC1 signaling in primary macrophages, antibodies to phopho-
S6K1 (Thr389), phospho-4E-BP1 (Ser65), phosph-S6 (Ser40/44), total S6K1, total S6 
and total 4E-BP1 were used. Antibodies to phospho-Akt (Thr308, Ser473), pan-Akt, 
phospho-Foxo1 (Thr24), Total Foxo1, phospho-GSK3$/# (Ser21/9), Total GSK3$/#, 
Total IRS2, phospho-STAT6 (Tyr641), total STAT6, and #-actin were also used. All 
antibodies were from Cell Signaling Technology. mTORC1 and Akt signaling antibodies 
and Aktvii inhibitor (EMD) were generously provided by Dr. Brendan Manning (Harvard 
School of Public Health). STAT6 antibodies and Troglitazone (Cayman) were generously 
provided by Dr. Chih-Hao Lee (Harvard School of Public Health). $-Tubulin antibody was 
purchased from Sigma Aldrich and rapamycin was purchased from LC Laboratories.  
Immunoblotting, qPCR, and ELISA 
For protein sample preparation, cells were washed twice with cold PBS following 
stimulation and lysed in 1% NP-40 buffer with EDTA-free protease inhibitor tablets 
(Roche Diagnostics) and phosphatase inhibitors (#-glycerophosphate, sodium fluoride, 
sodium orthovanadate). Protein concentration in lysates was determined using the 
Bradford method. For immunoblotting, 15µg of protein was loaded onto SDS-PAGE gels. 
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Gels were subsequently transferred onto PVDF membranes. Membranes were then 
blotted with primary antibodies as indicated. After primary antibody incubation, 
membranes were incubated with anti-rabbit or anti-mouse HRP secondary antibodies 
(GE Healthcare). Western blot membranes were developed using Femto or Pico ECL 
reagent (Thermo Fisher Scientific).  NIH ImageJ Software was used for densitometry. 
For RNA isolation, cells were collected in RNA-Bee (Tel-Test Inc.) followed by 
chloroform extraction and isopropanol precipitation according to the manufacturer’s 
instructions. RNA pellets were washed twice with 75% ethanol, dried and resuspended 
in water. RNA (1µg) was used for cDNA synthesis using the Applied Biosystems cDNA 
synthesis kit according to the manufacturer’s instructions. qPCR analysis was performed 
using Bio-Rad Sybr green reagent and the Bio-Rad Real-Time system. Transcript levels 
were normalized to HPRT and relative expression was plotted using the %%Ct method.  
To measure cytokine secretion by ELISA, cell culture supernatants were 
collected and debris was spun out by centrifugation at 3000xg, 5 min. Supernatants 
were diluted in assay diluent for TNF-$ ELISAs while supes were used undiluted for IL-
10 ELISA. All ELISA kits were purchased from BioLegend, and assays were performed 
according to the manufacturer’s instructions.  
Arginase Assays 
Arginase assay was described previously41. Briefly, 0.5x106 cells/well in 12-well 
plates were stimulated with 10ng/ml IL-4 for 12-48h. Cells were lysed in 0.1% TritonX-
100 lysis buffer. Lysates were incubated with 500mM of L-Arginine for 45 minutes at 
37°C, and the reaction was subsequently stopped with acid solution. The degradation of 
L-arginine to urea was measured by adding 9% isonitrosopropiophenone in 100% 
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ethanol and reading absorbance at 540nm in a microplate reader. All samples were read 
in triplicate.  
Fatty Acid Oxidation and Mitochondrial Mass Measurements 
Macrophages were plated 0.7x106 cells/well in 12-well tissue culture dishes in 
complete RPMI and stimulated with IL-4 for 24-36h. After stimulation, cells were washed 
with PBS and loaded with low glucose DMEM plus 2% fatty acid-free BSA for 30 minutes 
at 37°C. After 30 minutes, cells were washed twice with PBS and given 3H-labeled 
palmitic acid (2µCi/well) in low glucose DMEM plus 2% fatty acid-free BSA, plus 0.2mM 
unlabeled palmitic acid. After 4h, 100ul of media was collected and the isolation of 3H2O 
was performed using trichloroacetic acid followed by chloroform-methanol extraction. 
Water-soluble fractions were collected into 5ml of EcoLume scintillation fluid and 
counted for 5 minutes using a Beckman LS6500 scintillation counter. Cells were lysed in 
500µl of 0.1N NaOH and total protein was determined using the Bradford method. 
Background 3H was subtracted from the CPM value and all samples were normalized to 
mg of total protein. For mitochondrial mass, cells were plated 0.7x106 cells/well in low 
binding 12-well plates and stimulated with 10ng/ml IL-4 for 24h. After 24h, cells were 
stained with 25nM MitoTracker® Green (Invitrogren) for 30 min. Cells were then 
harvested in FACS buffer (PBS+2mM EDTA+0.5% FCS) and analyzed by flow 
cytometry using a BD FACSCalibur machine. All data was analyzed using FlowJo 
software (TreeStar).  
Results 
Confirmation of Tsc1fl/fl and Tsc1fl/fl LysMCre Mouse Genotype 
TSC1 (hamartin) is part of the tuberous sclerosis repressor complex that in 
partnership with TSC2 (tuberin) GAP activity regulates the Rheb, the small G-protein 
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that activates mTORC13. To study mTORC1 function in macrophages, we used a gain a 
function approach generating mice with myeloid specific deletion of Tsc1. We took 
advantage of the Cre-lox system and crossed Tsc1loxP/loxP mice with mice carrying 
transgenic Cre driven by the myeloid specific gene promoter, Lysozyme M, whose 
expression increases during macrophage differentiation26. Cre recombinase activity 
leads to deletion of exons 17 and 18 of Tsc1 as previously described27. To confirm the 
presence of the loxP alleles and the LysMCre transgene, tail DNA was analyzed by PCR 
with primers to wild-type and loxP Tsc1 and to the LysMCre transgene. Bone marrow 
derived macrophages from Tsc1loxP/loxP and Tsc1loxP/loxP LysMCre mice, herein referred to 
as Tsc1fl/fl and Mac-Tsc1KO respectively, were used in subsequent experiments. Tsc1 
knockdown or deletion leads to constitutive mTORC1 activity independent of nutrients, 
growth factors and upstream PI3kinase/Akt signaling2. To verify that Mac-Tsc1KO bone 
marrow derived macrophages have constitutive mTORC1 activity, MCSF-differentiated 
BMDMs were incubated in the presence or absence of serum and the specific mTORC1 
inhibitor, rapamycin. Western blotting shows that TSC1 is present in Tsc1fl/fl 
macrophages, but absent in the Mac-Tsc1KO BMDMs, indicating that recombination 
was successful (Figure 1a). Since TSC1 stabilizes, TSC2, Mac-Tsc1KO BMDMs also 
have diminished TSC2 protein (Figure 1a). Further western blot analysis examining 
mTORC1 downstream targets reveals that Mac-Tsc1KO BMDMs have high basal 
phosphorylation S6K1 at threonine 389 and 4E-BP1 at serine 65 (Figure 1a). The 
mTORC1-specific inhibitor, rapamycin diminishes the constitutive phosphorylation S6K1 
and 4E-BP1 in Mac-Tsc1KO BMDMs (Figure 1a). 
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Inflammatory Phenotype of Mac-Tsc1KO BMDMs 
Several studies have implicated mTORC1 in the modulation of immune function 
through the use of rapamycin, but the literature is quite conflicting due to off target 
effects of this drug. Studies using myeloid-specific genetic models to determine the role 
of mTOR in innate immune cells are lacking. In one recent study, investigators used a 
tamoxifen-inducible ubiquitin-cre system to delete Tsc1 in vivo, and found that bone 
marrow derived macrophages from mice injected with tamoxifen displayed enhanced 
secretion of pro-inflammatory cytokines IL-6 and TNF-$, which was attributed to 
increased JNK activity28. Consistent with these findings, we show that upon LPS 
challenge that promotes an M1 phenotype, Mac-Tsc1KO BMDMs have enhanced 
secretion of the pro-inflammatory cytokine, TNF-$, and reduced secretion of the anti-
inflammatory cytokine, Interleukin-10 by ELISA (Figure 1b). In addition, gene expression 
analysis reveals enhanced expression of pro-inflammatory cytokines TNF-$, IL-6, and 
IL-12p40 in Mac-Tsc1KO BMDMs when stimulated with LPS (data not shown). The 
increase in TNF-$ secretion in Mac-Tsc1KO BMDMs was inhibited by rapamycin, 
indicating that constitutive mTORC1 promotes a pro-inflammatory phenotype (Figure 
1c).  
 
Mac-Tsc1KO BMDMs have Defective M2 Polarization 
Given that Mac-Tsc1KO BMDMs display a pro-inflammatory phenotype, we 
hypothesized that there may be a defect in M2 polarization. When stimulated with the 
Th2 cytokine IL-4, Mac-Tsc1KO BMDMs display a marked failure to upregulate genes 
involved in M2 polarization. Mac-Tsc1KO BMDMs have a 2-3-fold reduction in Arginase-
1, Mgl1, and Fizz1 mRNA expression relative to Tsc1fl/fl controls (Figure 2a). Consistent 
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with Arginase-1 gene expression, Arginase-1 activity indicated by urea production is 2-
fold lower in Mac-Tsc1KO BMDMs relative to Tsc1fl/fl controls (Figure 2a). The defect in 
M2 gene expression in Mac-Tsc1KO BMDMs is not dose-dependent, as the defective 
induction of Arginase-1, Fizz1, and PGC-1! is present even when cells are stimulated 
with up to 100ng/ml IL-4 (data not shown). Given that the nuclear receptors PPAR! and 
PPAR" are known regulators of M2 polarization and that mTORC1 was shown to 
regulate PPAR! expression in adipose tissue, we analyzed gene expression of both 
PPAR# and PPAR". We found that the mRNA expression levels of both Ppar# and 
Ppar" were unaffected in the Mac-Tsc1KO BMDMs at basal state and upon IL-4 
stimulation (Figure 2b). Since PPAR gene expression levels were normal in the Mac-
Tsc1KO BMDMs, we next wanted to check gene expression of Pgc-1!, the PPAR 
transcriptional coactivator also shown to be critical for M2 polarization. Indeed, mRNA 
levels of Pgc-1! were reduced approximately 2-fold in IL-4 stimulated Mac-Tsc1KO 
BMDMs relative to Tsc1fl/fl controls (Figure 2c). Consistent with the role of PGC-1# in 
promoting the fatty acid oxidation program of M2 macrophages, Mac-Tsc1KO BMDMs 
show impaired beta oxidation of palmitic acid, producing approximately 2-fold less 3H2O 
from labeled palmitic acid than Tsc1fl/fl controls (Figure 2c).  Furthermore, mitochondrial 
biogenesis as measured by flow cytometry using MitoTracker® Green staining is 
modestly increased by IL-4 stimulation in Tsc1fl/fl BMDMs, while this increase is not 
observed in Mac-Tsc1KO BMDMs (Figure 2c). Stimulation of macrophages with IL-4 
leads to IL-4 Receptor-dependent activation of JAK1, phosphorylation of STAT6 at 
tyrosine 641, dimerization and nuclear translocation12,14. When stimulated with IL-4 for 
15min up to 2h, Mac-Tsc1KO BMDMs display normal, if not enhanced, phosphorylation 
of STAT6 at tyrosine 641, while total STAT6 levels were comparable between Mac-
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Tsc1KO and Tsc1fl/fl BMDMs (Figure 2d). Furthermore, nuclear/cytosolic fractionation 
shows that phosphorylated STAT6 nuclear translocation was normal in Mac-Tsc1KO 
BMDMs, indicating that proper JAK1/STAT6 signaling is intact (Figure 2e). Taken 
together, these results indicate that constitutive mTORC1 in macrophages leads to 
defective M2 polarization despite normal PPAR expression and intact canonical IL-4 
Receptor signaling. 
Mac-Tsc1KO BMDMs have Diminished mTORC2 Activity and Attenuated Akt Signaling 
Tsc1-null MEFs and hepatocytes both display attenuated insulin stimulated Akt 
signaling and reduced phosphorylation of downstream Akt targets2,6.  Another 
characteristic of Tsc1-null MEFs and hepatocytes that further impairs insulin signaling 
S6K1-mediated serine phosphorylation of IRS-1, which destabilizes the protein and 
reduces activation of PI3K/Akt signaling2,6. Previous studies demonstrate that the IL-4 
Receptor, particularly the IL-4R$ chain, engages IRS2 leading to tyrosine 
autophosphorylation, and downstream activation of the PI3K/Akt/mTOR pathway24. We 
thus hypothesized that Mac-Tsc1KO BMDMs would have attenuated Akt in response to 
IL-4 stimulation similar to attenuated insulin signaling in other Tsc1-null cell lines. 
Indeed, western blot analysis shows that IL-4 stimulated Mac-Tsc1KO BMDMs display 
reduced phosphorylation of Akt at serine 473, the mTORC2 site, and at threonine 308, 
the PDK1 site (Figure 3a). Total Akt levels were comparable between Tsc1fl/fl and Mac-
Tsc1KO Macrophages, although there is a downward mobility shift in Mac-Tsc1KO 
BMDMs (Figure 3a). Consistent with attenuated Akt signaling, phosphorylation of the Akt 
target FOXO1 is also reduced in the Mac-Tsc1KO BMDMs; however, phosphorylation of 
the Akt targets GSK3$/# is unaffected in Mac-Tsc1KO BMDMs (Figure 3a). GSK3$/# 
lies downstream of many signaling pathways, such as the Wnt and Ras pathways, which 
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could account for the normal phosphorylation levels29. Total IRS2 levels were reduced in 
IL-4 stimulated Mac-Tsc1KO BMDMs consistent with serine phosphorylation leading to 
protein destabilization and enhanced degradation (Figure 3a). Concomitant with 
attenuated Akt, Tsc1-null MEFs also have diminished growth factor stimulated mTORC2 
activity due to the mTORC1 negative feedback inhibition of upstream PI3K and loss of 
the tuberous sclerosis repressor complex necessary for mTORC2 activation3,30,31. 
Following activation by PI3K, mTORC2 phosphorylates downstream targets SGK1 and 
PKC-$ in addition to Akt on serine 47331. To assess mTORC2 activity in Mac-Tsc1KO 
BMDMs, phosphorylation of NDRG1, a target of SGK1 was examined by western blot. 
Consistent with other Tsc1-null cell types, IL-4 stimulated Mac-Tsc1KO BMDMs display 
reduced phosphorylation of NDRG1 at threonine 346 relative to Tsc1fl/fl controls, 
indicating that mTORC2 activity is diminished (Figure 3a).  
M2 Polarization is not defective in Rictor-null BMDMs 
To complement the Tsc1-deficiency model that is characterized by attenuated 
mTORC2 and PI3K/Akt signaling, we took advantage of a tamoxifen-inducible ubiquitinC 
CreERT2 model to delete Rictor, the key component of mTORC2. Macrophages isolated 
from Rictorfl/fl and Rictorfl/fl Ub-Cre mice injected with tamoxifen were stimulated with IL-4 
similar to the Mac-Tsc1KO BMDMs. Western blot analysis shows that Rictor protein 
expression is completely ablated in the Rictorfl/fl Ub-Cre BMDMs indicating that cre-
recombinase was successful (Figure 3b). Surprisingly, Arginase-1 activity is not reduced 
in the Rictorfl/fl Ub-Cre BMDMs, which is consistent with normal gene expression of 
Arginase-1 (Figure 3c). Furthermore, gene expression of other M2 markers, Pgc-1!, 
Mgl1, and Fizz1 is unaffected in IL-4 stimulated Rictor-null BMDMs (Figure 3c and data 
not shown). Western blot analysis reveals that Akt phosphorylation at serine 473 is 
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completely absent in the Rictor-null macrophages as expected and phosphorylation of 
FOXO1 is also reduced. STAT6 phosphorylation is also normal in the Rictor-null 
BMDMs, unlike the Rictor-null T-cells8. Interestingly, unlike the Mac-Tsc1KO BMDMs, 
phosphorylation of Akt at threonine 308 is intact in Rictor-null BMDMs, although there is 
a downward mobility shift likely due to decreased serine 473 phosphorylation (Figure 
3b). One study suggests that Akt phosphorylation at threonine 308 is most critical for 
activity, whereas the serine 473 site is necessary for FOXO1 phosphorylation and 
hyperactivation of Akt32. Thus, loss of mTORC2 in Rictor-null macrophages is not 
sufficient to produce a defect in M2 polarization, which implicates phosphorylation of Akt 
at threonine 308 downstream of IRS2/PI3K/PDK1 as a critical event for induction of the 
M2 genetic program.   
Akt Regulates a Subset of M2 Macrophage Markers 
Mac-Tsc1KO BMDMs display reduced mTORC2 activity and attenuated Akt 
signaling, yet loss of mTORC2 and serine 473 phosphorylation of Akt is not sufficient to 
produce a defect in M2 polarization. Akt signaling is known to increase with IL-4 
stimulation in macrophages, yet the downstream consequences are unclear. To 
investigate the role of Akt in M2 polarization, we treated WT BMDMs with Aktviii inhibitor, 
which inhibits Akt phosphorylation and activity. WT BMDMs pre-treated with Aktviii for 1h 
prior to IL-4 stimulation for 12h and 24h display reduced mRNA expression of the M2 
genes Arg-1, Fizz1, Mgl1, and Pgc-1!, all of which are downregulated in Mac-Tsc1KO 
BMDMs (Figure 4a). Consistent with gene expression results, Arginase-1 activity is 
completely absent in WT BMDMs treated with IL-4+Aktviii at 12h and 24h (Figure 4a). 
Gene expression of other M2 macrophage markers, such as Mrc1, and Ym1 is not 
affected by treatment with Aktviii (Figure 4a). Western blot analysis shows that treatment 
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with Aktviii prior to IL-4 stimulation abolishes Akt phosphorylation at both serine 473 and 
threonine 308 as observed in Mac-Tsc1KO BMDMs, in addition to decreasing 
phosphorylation of FOXO1 and GSK3$/# (Figure 4b). Furthermore, STAT6 
phosphorylation is unaffected by Aktviii treatment prior to IL-4 stimulation (Figure 4b). A 
study performed in adipocytes showed that the Akt target, FOXO1, is able to 
transrepress rosiglitazone-induced PPAR! activity33. Since attenuated Akt signaling 
leads to reduced phosphorylation and likely increased nuclear content of FOXO1, this 
could account for the defective M2 polarization observed in Mac-Tsc1KO BMDMs given 
the importance of PPAR! in this process (Figure 3a). While PPAR# mRNA levels are 
normal in Mac-Tsc1KO BMDMs (Figure 2c), the transcriptional activity could be 
disrupted by FOXO1 transrepression. To address this as a potential mechanism, we 
used the PPAR! agonist troglitazone in conjunction with IL-4 stimulation. Treatment of 
Mac-Tsc1KO BMDMs with troglitazone and IL-4 for 24h failed to rescue the defective 
mRNA expression of Arginase-1, Fizz1, Mgl1, and PGC-1! (Figure 4c). Moreover, 
expression of known PPAR!-dependent genes Fabp4 and Cd36, are normal in Mac-
Tsc1KO BMDMs, and IL-4 synergizes with troglitazone in increasing expression of these 
genes above IL-4 treatment alone in both Mac-Tsc1KO BMDMs and Tsc1fl/fl controls 
(Figure 4c). In conclusion, results from WT macrophages treated with Aktviii inhibitor 
provides support for attenuated Akt signaling, particularly reduced PDK1 
phosphorylation of threonine 308, as a mechanism for defective M2 polarization in Mac-
Tsc1KO BMDMs. In addition, FOXO1 transrepression of PPAR! that could occur 
downstream of attenuated Akt is unlikely the cause for the defective M2 polarization 
Mac-Tsc1KO BMDMs. Taken together, these results provide evidence that Akt signaling 
is necessary for induction of M2 macrophage markers.  
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Figure 1. Constitutive mTORC1 in BMDMs leads to a pro-inflammatory phenotype. 
a. Western blot analysis of Tsc1fl/fl and Mac-Tsc1KO BMDMs in the presence or absence 
of 20nM rapamycin for 15h. 
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Figure 1 (continued). Constitutive mTORC1 in BMDMs leads to a pro-inflammatory 
phenotype. b. TNF-$ and Interleukin-10 ELISAs in supernatants from Tsc1fl/fl and Mac-Tsc1KO 
BMDMs stimulated with 10ng/ml LPS for 2h and 6h. c. TNF-$ ELISA in supernatants from Tsc1fl/fl 
and Mac-Tsc1KO BMDMs stimulated for 6h in the presence or absence rapamycin (20nM, 1h 
pre-treatment). 
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Figure 2. Defective M2 Polarization in Mac-Tsc1KO BMDMs. a. IL-4 fails to induce M2 genes 
expression in Mac-Tsc1KO BMDMs. Data plotted as normalized fold expression of Arg1, Fizz1, 
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and Mgl1 mRNA levels in Tsc1fl/fl and Mac-Tsc1KO BMDMs stimulated with 10ng/ml IL-4 for 24-
48h. Arginase activity with 10ng/ml IL-4 for 24-48h as measured by urea production (µg) and 
normalized to total protein (µg). 
 
 
                  
 
Figure 2. Defective M2 Polarization in Mac-Tsc1KO BMDMs. b. PPAR Expression is 
unaffected in Mac-Tsc1KO BMDMs. Normalized fold expression of Ppar" and Ppar# in Tsc1fl/fl 
and Mac-Tsc1KO BMDMs stimulated with 10ng/ml IL-4 for 24h. 
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Figure 2 (continued). Defective M2 Polarization in Mac-Tsc1KO BMDMs.  
c. 
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c. Defective Pgc-1! mRNA expression is concomitant with reduced palmitic acid oxidation and 
mitochondrial biogenesis in Mac-Tsc1KO BMDMs stimulated with 10ng/ml IL-4 for 24-48h. FA 
oxidation plotted as fold induction over basal state (n=2). Mitochondrial biogenesis shown as 
measured by flow cytometery using MitroTracker® Green. 
 
 
 
    
 
 
Figure 2 (continued): Defective M2 Polarization in Mac-Tsc1KO BMDMs. d. STAT6 
phosphorylation and nuclear translocation is Intact in Mac-Tsc1KO BMDMs. Immunoblot analysis 
of p-STAT6Tyr641 and Total Stat6 in Tsc1fl/fl and Mac-Tsc1KO BMDMs stimulated with 10ng/ml IL-4 
for 15min-2h. Nuclear/cytosolic fractions from Tsc1fl/fl and Mac-Tsc1KO BMDMs stimulated with 
10ng/ml IL-4 for 30min-1h were blotted with p-STAT6Tyr641 as well as LaminA/C and $-Tubulin to 
verify fractionation. 
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Figure 2 (continued): Defective M2 Polarization in Mac-Tsc1KO BMDMs. e. Nuclear/cytosolic 
fractions from Tsc1fl/fl and Mac-Tsc1KO BMDMs stimulated with 10ng/ml IL-4 for 30min-1h were 
blotted with p-STAT6Tyr641 as well as LaminA/C and $-Tubulin to verify fractionation. 
 
 
 
 
 
Figure 3. Mac-Tsc1KO BMDMs have attenuated IRS2/PI3K/Akt Signaling and Reduced 
mTORC2 Activity. a. Immunoblot analysis of Tsc1fl/fl and Mac-Tsc1KO BMDMs stimulated with 
10ng/ml IL-4 for 15min-2h to examine IRS2/PI3K/Akt Signaling. Mac-Tsc1KO BMDMs have 
reduced IL-4-induced Akt phosphorylation and well reduced mTORC2 activation.  
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Figure 3 (continued). Mac-Tsc1KO BMDMs have attenuated IRS2/PI3K/Akt Signaling and 
Reduced mTORC2 Activity. b. Immunoblot analysis of Rictorfl/fl and Rictorfl/flUb-Cre BMDMs 
stimulated with 10ng/ml for 5min-2h. Rictorfl/flUb-Cre BMDMs have reduced AktS473 
phosphorylation, but intact AktThr308 phosphorylation with IL-4 stimulation.  
  
Total Rictor 
p-Akt
S473
 
p-Akt
Thr308
 
p-STAT6
Tyr641
 
!-Tubulin 
Un
tre
ate
d 
15’ 30’ 1h 2h 5’ 
Rictor
fl/fl
 Rictor
fl/fl 
Ub-Cre 
p-NDRG1
Thr346
 
b. 
Un
tre
ate
d 
15’ 30’ 1h 2h 5’ 
 26 
 
 
Figure 3 (continued). Mac-Tsc1KO BMDMs have attenuated IRS2/PI3K/Akt Signaling and 
Reduced mTORC2 Activity  c. M2 polarization in Rictorfl/flUb-Cre BMDMs is not defective. 
Arginase activity with 10ng/ml IL-4 for 12-48h as measured by urea production (µg) and 
normalized to total protein (µg). Normalized fold expression of Arg-1 and Pgc-1! mRNA levels 
are shown in Rictorfl/fl and Rictorfl/flUb-Cre BMDMs stimulated with 10ng/ml for 12-48h.  
c
.
Untreated 12h 24h 36h 48h
0.0
0.5
1.0
1.5
2.0
Ur
ea
 P
ro
du
ct
io
n 
(µ
g)
 / µ
g 
pr
ot
ei
n Rictor
fl/fl
Rictorfl/flUb-Cre
IL-4
Untreated 12h 24h 36h 48h
0
5000
10000
15000
No
rm
 A
rg
1 
Ex
pr
es
si
on
Rictorfl/fl
Rictorfl/flUb-Cre
IL-4
Untreated 12h 24h 36h 48h
0
5
10
15
No
rm
 P
gc
-1
! 
Ex
pr
es
si
on
Rictorfl/fl
Rictorfl/flUb-Cre
IL-4
 27 
 
       
              
   
 
Figure 4. Akt Regulates a Subset of M2 Genes Independent of FOXO1. a. Pharmacological 
inhibition of Akt reduces M2 gene expression. Normalized fold expression of Arg1, Fizz1, Pgc-1!, 
Mgl1, Ym1, and Mrc1 mRNA levels in WT BMDMs treated with 10ng/ml IL-4 for 12h or 24h in the 
presence or absence of 10µM Aktviii, 1h pre-treatment. 
  
Figure 4 
a. 
Un
tre
ate
d
IL-
4 1
2h
IL-
4+
Ak
tvi
ii 1
2h
IL-
4 2
4h
IL-
4+
Ak
tvi
ii 2
4h
0
5
10
15
20
N
or
m
 A
rg
1 
Ex
pr
es
si
on
Un
tre
ate
d
IL-
4 1
2h
IL-
4+
Ak
tvi
ii 1
2h
IL-
4 2
4h
IL-
4+
Ak
tvi
ii 2
4h
0
20
40
60
80
N
or
m
 F
iz
z1
 E
xp
re
ss
io
n
N
or
m
 P
gc
-1
! 
Ex
pr
es
si
on
Un
tre
ate
d
IL-
4 1
2h
IL-
4+
Ak
tvi
ii 1
2h
IL-
4 2
4h
IL-
4+
Ak
tvi
ii 2
4h
0
10
20
30
40
50
N
or
m
 M
gl
1 
Ex
pr
es
si
on
 
Un
tre
ate
d
IL-
4 1
2h
IL-
4+
Ak
tvi
ii 1
2h
IL-
4 2
4h
IL-
4+
Ak
tvi
ii 2
4h
0
2
4
6
WT BMDMS  
No
rm
 F
ol
d 
 Y
m
1 
Ex
pr
es
io
n
Un
tre
ate
d
IL-
4 1
2h
IL-
4+
Ak
tvi
ii 1
2h
IL-
4 2
4h
IL-
4+
Ak
tvi
ii 2
4h
0
50
100
150
No
rm
 F
ol
d 
M
rc
1 
Ex
pr
es
si
on
Un
tre
ate
d
IL-
4 1
2h
IL-
4+
Ak
tvi
ii 1
2h
IL-
4 2
4h
IL-
4+
Ak
tvi
ii 2
4h
0
2
4
6
8
10
 28 
 
 
 
Figure 4 (continued). Akt Regulates a Subset of M2 Genes Independent of FOXO1.  
b. Immunoblot analysis of WT BMDMs stimulated with 10ng/ml for 30min-2h in the presence of 
absence of 10µM Aktviii, 1h pre-treatement.  
WT BMDMs 
p-Akt
S473
 
p-Akt
Thr308
 
Total Akt 
p-FOXO1
Thr24
 
Total FOXO1 
p-GSK3!/"
S21/9
 
Total GSK3!/" 
p-STAT6
Tyr641
 
Total STAT6 
!-Tubulin 
IL-4 
Aktviii + + + + 
1h 
+ + + 
30
’
2
h
1h 
+ + + 
30’ 2h 
b. 
 29 
  
 
 
Figure 4 (continued). Akt Regulates a Subset of M2 Genes Independent of FOXO1. c. 
Transrepression of PPAR! by FOXO1 does not account for defective M2 polarization in Tsc1fl/fl 
and Mac-Tsc1KO BMDMs. Tsc1fl/fl and Mac-Tsc1KO BMDMs treated with 10ng/ml IL-4 in the 
presence or absence of 1µM troglitazone (co-treatment) for 24h. Normalized fold expression of 
Arg1, Fizz1, Pgc-1!, Mgl1, Fabp4, and Cd36 mRNA levels are shown. 
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Discussion 
     In this study, we use a novel model of myeloid-specific Tsc1 deletion and constitutive 
mTORC1 activity to elucidate mTOR function in macrophages. Consistent with previous 
findings in Pan et al 2012, we show that Tsc1 deficiency in macrophages leads to a pro-
inflammatory phenotype upon stimulation with LPS, with Mac-Tsc1KO BMDMs 
displaying increased secretion of pro-inflammatory TNF-$ and decreased secretion of 
anti-inflammatory IL-10 relative to Tsc1fl/fl controls. We show, for the first time, that IL-4 
stimulated Mac-Tsc1KO BMDMs have defective M2 polarization displaying reduced 
mRNA expression of key M2 markers Arginase-1, Fizz1, Mgl1/2 and the PPAR! 
transcriptional coactivator, Pgc-1! relative Tsc1fl/fl controls. Mac-Tsc1KO BMDMs also 
exhibit defects in IL-4 induced mitochondrial biogenesis and fatty acid oxidation, PGC-
1#- dependent processes. Examination of IL-4 signal transduction reveals that Mac-
Tsc1KO BMDMs have reduced IRS2 stability, attenuated Akt signaling, and diminished 
mTORC2 activity due to the mTORC1 negative feedback loops that inhibit upstream 
IRS/PI3K signaling. Loss of mTORC2 and mTORC2-mediated phosphorylation of Akt at 
serine 473 that occurs in Rictor-null macrophages is insufficient to produce a defect in 
M2 polarization. Instead, intact Akt threonine 308 phosphorylation in response to IL-4 
may critical downstream of IL-4R signaling for induction of M2 genes. Consistent with 
this, pharmacological inhibition of Akt with Aktviii inhibitor produces a defect in M2 
polarization and blocks phosphorylation of Akt at both, serine 473 and threonine 308, 
mimicking the effects of the mTORC1-mediated negative feedback loops in the Mac-
Tsc1KO BMDMs. The data thus support a critical role for IRS2/PI3K activation of PDK1 
and phosphorylation of Akt at threonine 308 downstream of the IL-4 Receptor in parallel 
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with the JAK/STAT6 signal transduction pathway for maximal induction of the M2 
polarization program in macrophages.  
Several published reports highlight the importance of Akt in macrophage 
polarization. A recent study proposes that different Akt isoforms regulate M1 versus M2 
polarization in macrophages, with Akt1 being important for M2 polarization and Akt2 
being important for M1 polarization through differential regulation of miR155 and the 
transcription factor C/EBP-#34.  The investigators, however, use LPS stimulation to 
examine expression M2 gene markers instead of the Th2 cytokine IL-4. Furthermore, 
expression of Akt2 is controversial in macrophages, as one study demonstrates that 
Akt1 is the predominant isoform in both bone marrow derived macrophages and 
peritoneal macrophages, while levels of Akt2 are undetectable35. Another recent study 
implicates Akt in the regulation of M2 macrophage proliferation and enhancement both in 
vitro and in vivo36. In this study, investigators use IL-4R$-/- mice that have defective 
engagement of IRS2/PI3K/Akt in response to IL-4 to show that Akt signaling is 
necessary for M2 macrophage polarization during helminth infection, a Th2-driven 
process. Our study elaborates on these findings by examining Akt signaling downstream 
of IL-4R in M2 polarization, as well as defining a specific subset of genes whose 
expression is downregulated when IRS2/PI3K/Akt signaling is disrupted, either by 
mTORC-1 mediated negative feedback loops or by pharmacological inhibition of Akt. 
Genes such as Arginase-1, Fizz1, the C-type lectins Mgl1/2 and Pgc-1! have all been 
implicated as STAT6-dependent genes through analysis STAT6-/- macrophages14,23. Our 
data shows that STAT6 signaling is intact in both the Mac-Tsc1KO BMDMs and with 
pharmacological inhibition of Akt, which demonstrates that IRS2/PI3K/Akt signaling is 
critical for induction of key M2 markers independent of STAT6. A surprising finding of our 
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study was the lack of PPAR! and PPAR" involvement in the phenotype of the Mac-
Tsc1KO BMDMs, given their established importance in M2 polarization. mTORC1 was 
shown to have differing effects on PPAR isoforms in various tissues. For example, in 
Tsc1KO liver, mTORC1 inhibits PPAR$- mediated beta oxidation and ketogenesis, 
whereas in Tsc1KO adipocytes, mTORC1 drives PPAR!-mediated adipogenesis7,37. The 
inability of the PPAR! agonist troglitazone to rescue the M2 polarization defect in our 
model rules out the possibility of direct mTORC1 regulation of PPAR!. While we cannot 
definitively rule out mTORC1 inhibition of PPAR", decreased Pgc-1! in Mac-Tsc1KO 
BMDMs is likely more significant for the observed phenotype in these cells. A previous 
report shows that PGC-1# is necessary for induction of Arginase-1 activity and the 
metabolic program to support energy demands of M2 macrophages through the 
regulation of fatty acid oxidation22. The current model proposes that IL-4 signaling leads 
to JAK/STAT6 activation and STAT6 subsequently increases transcription of M2 genes, 
including PGC-1#14. PGC-1# then serves as a transcriptional coactivator of STAT6 to 
increase genes involved in oxidative metabolism as well as to increase expression and 
activity of PPAR! and –"14. Our findings in Mac-Tsc1KO BMDMs implicate PI3K/Akt 
signaling downstream of IL-4R as a necessary event to increase PGC-1! expression. It 
is plausible that the parallel IRS2/PI3K/Akt signaling pathway is necessary for 
upregulation of Pgc-1! expression, which then coactivates STAT6 transcription of the 
M2 genes Arg1, Fizz1, and Mgl1/2; however, other approaches to assess STAT6 DNA 
binding and transcriptional activity would be necessary to confirm this in Mac-Tsc1KO 
BMDMs.  
A key experiment to demonstrate that the negative feedback inhibition by 
mTORC1 upstream leads to the M2 polarization defect would be to pharmacologically 
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inhibit mTORC1 with the allosteric inhibitor, rapamycin. In Tsc1-deficient hepatocytes 
and MEFs, rapamycin treatment relieves the negative feedback loops and leads to 
increased Akt phosphorylation at both serine 473 and threonine 3082,6. While rapamycin 
is a specific inhibitor of mTORC1, at certain concentrations and time points, this drug 
has off target effects, most notably inhibition of mTORC238. Given that M2 polarization 
experiments require a long incubation with IL-4 for Arginase-1 activity and for metabolic 
assays, it would be difficult to draw conclusions with the possibility of both known and 
unknown off target effects. Knockdown of raptor, the key component of mTORC1, would 
be more suitable to address this question, but these studies are challenging in primary 
macrophages.  
    The PI3K/Akt/mTOR pathway is a key nutrient and energy sensing pathway activated 
in response to insulin and other growth factors5,38. Chronic activation of mTORC1 by 
nutrient excess, as observed in obesity, leads to inhibition of the insulin response 
through negative feedback loops, which has pathological consequences for tissues, 
such as adipose, muscle, and liver1,5. The combination of increased glucose output by 
liver, increased insulin production by pancreatic beta cells, and the increase in 
circulating fatty acids due to unrestrained adipose tissue lipolysis observed in obesity 
creates a milieu that bombardes peripheral tissues with nutrients leading to aberrant 
mTORC1 activity in many tissues1. The negative feedback inhibition of mTORC1 on 
upstream PI3K/Akt signaling that likely serves to maintain inducibility of these signals, 
becomes chronically inhibited leading to attenuation of insulin responses and ultimately, 
insulin resistance that precedes Type 2 Diabetes development5. A chronic low-grade 
inflammation also accompanies metabolic dysfunction in key insulin responsive tissues 
in obesity, such as liver and adipose tissue, where resident macrophages undergo a 
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phenotypic switch from anti-inflammatory M2 macrophages to pro-inflammatory M1 
macrophages, further exacerbating insulin resistance16. We believe that Mac-Tsc1KO 
macrophages could serve as model for adipose tissue macrophages during obesity. 
Macrophages in adipose tissue are bathed with the same excess nutrients that other 
peripheral tissues encounter, and we believe this could lead to chronic mTORC1 
activation. The elevated mTORC1 activity then inhibits upstream IRS2/PI3K/Akt 
signaling rendering the macrophages “resistant” to IL-4, and thus unable to polarize to 
an M2 phenotype. Macrophages with elevated mTORC1 also display enhanced pro-
inflammatory responses to TLR4 ligand LPS, a response that could be elicited by 
increased saturated fatty acid binding to TLR4 in obesity17. In the future, it would be 
interesting to examine mTORC1 and IL-4 signaling in macrophages from mice with a 
genetic model of obesity, such as ob/ob mice, or from mice fed a high fat diet. It would 
also be interesting to see if mice with Tsc1 deletion in myeloid lineage cells would have 
worsened obesity and metabolic dysregulation on a high fat diet. Unfortunately, due to 
epileptic seizures and premature death in Mac-Tsc1KO mice, these studies are not 
feasible. Perhaps utilization of another genetic model could better address the 
macrophage mTOR signaling in obesity.  
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